AUT1

CAS No. 1311136-84-1

AUT1 ( —— )

Catalog No. M19956 CAS No. 1311136-84-1

AUT1 (AUT-1) is a novel specific modulator of Kv3 channels (EC50: 4.7 and 4.9 uM for Kv3.1b and Kv3.2a).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 87 In Stock
10MG 129 In Stock
25MG 228 In Stock
50MG 372 In Stock
100MG 556 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    AUT1
  • Note
    Research use only not for human use.
  • Brief Description
    AUT1 (AUT-1) is a novel specific modulator of Kv3 channels (EC50: 4.7 and 4.9 uM for Kv3.1b and Kv3.2a).
  • Description
    AUT1 (AUT-1) is a novel specific modulator of Kv3 channels (EC50: 4.7 and 4.9 uM for Kv3.1b and Kv3.2a).
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Potassium Channel
  • Recptor
    Kv3.1b channels; Kv3.2a channels
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1311136-84-1
  • Formula Weight
    341.37
  • Molecular Formula
    C18H19N3O4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 250 mg/mL (732.36 mM)
  • SMILES
    CC[C@H]1NC(=O)N(C1=O)c1ccc(Oc2ccc(C)c(OC)c2)nc1
  • Chemical Name
    (5R)-5-Ethyl-3-(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)-24-imidazolidinedione

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Rosato-Siri MD et al. A Novel Modulator of Kv3 Potassium Channels Regulates the Firing of Parvalbumin-Positive Cortical Interneurons. J Pharmacol Exp Ther. 2015 Sep;354(3):251-60.
molnova catalog
related products
  • ICA

    ICA is a SK channel inhibitor and exhibits antileishmanial activity (IC50: 2.1 μM).

  • KCNQ1 activator-1?

    2-Piperidinecarboxamide, N-[4-(4-methoxyphenyl)-2-thiazolyl]-1-(phenylsulfonyl)- is a potent KCNQ1 channel activator that can be used in long QT syndrome (LQTS) studies.

  • XE-991

    XE-991 is a potent, selective and orally active blocker of voltage-gated potassium channels Kv7 (KCNQ) that blocks KCNQ1, KCNQ2 and KCNQ2+KCNQ3 with Kd of 0.78, 0.7 and 0.6 uM, respectively.